Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the… read more.
Results from a Phase 3 study of treatment with investigational tolebrutinib show a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing… read more.
Sudden cardiac death (SCD) refers to an unexpected death of a person, believed to be caused by a heart-related issue. It occurs within one hour of the onset… read more.
29th EAHP Congress highlights Anticholinergic burden (AB) or anticholinergic load (AL) refers to the cumulative effect of taking multiple medications with anticholinergic actions, which can lead to adverse effects,… read more.
29th EAHP Congress highlights Biopharmaceuticals are complex biological molecules that require careful storage and handling to ensure medication integrity. They are especially sensitive to mechanical stress and shaking,… read more.
The NHS could prevent thousands more heart attacks and strokes every year by offering everyone in the UK aged 50 and over a single “polypill” combining a statin… read more.
Eton Pharmaceuticals Inc announced that it has launched Galzin (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially… read more.
The European Medicines Agency (EMA) has recommended four new products for approval, and extended the use of sixteen other drugs. The decisions, which brings to 12 the total… read more.
The use of the anti-contraction (tocolytic) drug atosiban in cases of threatened premature birth after 30 weeks of pregnancy is not more effective than placebo at reducing poor… read more.
Sandoz, announces the launch of Pyzchiva (ustekinumab-ttwe) in the US. Developed by Samsung Bioepis Co., Ltd., and marketed by Sandoz, Pyzchiva has been approved by the FDA for… read more.
Generic drugs manufactured in India are linked to significantly more “severe adverse events” for patients who use them than equivalent drugs produced in the United States, a new… read more.
Repurposing amlodipine, a commonly used blood pressure medicine, could help manage attention-deficit/ hyperactivity disorder (ADHD) symptoms, according to an international study involving the University of Surrey. In a… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
